DGAT1 and metabolic disease: As the metabolic phenotypes of DGAT1 null mice are lost when DGAT1 is reintroduced into the intestine [6], we raised a hypothesis that the intestine-targeted DGAT1 inhibitor would improve metabolic disorders with minimizing the adverse effect that may be driven by systemic DGAT1 inhibition.